What we offer to patients and their families
We offer a detailed review of the medical history and images by an international team of experts specialized in the care of DIPG/DMGs. This will allow us to provide you with the best current treatment recommendations for your child. We will then schedule a video consultation with you and your family to discuss our recommendations. This could include:
- Biopsy or further resection of the tumors
- Participation in a clinical trial
- Genomic analyses of the tumor tissue
We are offering second opinions after detailed review of medical records, existing molecular data and images. Each patient will be discussed in the trans-Atlantic DIPG/DMG dedicated tumorboard with experts of the University Children’s Hospital Zurich and UCSF. This procedure allows to provide a recommendation for further steps in the medical care based on a broad expert opinion. We can offer second opinions either through in person visits or via telemedicine (video conferencing) in English, French or German, but when needed, we will be happy to set up a phone call with an interpreter.
Please email firstname.lastname@example.org to request a second opinion.
Biopsies for molecular analysis of the tumor
Real time expansion, characterization and drug screen using patient’s derived DMG cells
At the DIPG/DMG Center Zurich we are actively working on developing and implementing effective and novel clinical trials for patients diagnosed with DIPG and DMG. We are offering clinical trial enrollment but also work with several companies for compassionate use strategies if trial enrollment is not an option.
We are member of the Pacific Pediatric Neuro-Oncology Consortium. Please see all PNOC open trials here: www.pnoc.us
At the DIPG/DMG Center in Zurich we offer enrollment into the following trials.
PNOC016: A Target Validation Study of Fimepinostat in Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG)
ClinicalTrials.gov Identifier: NCT03893487
PNOC007: H3.3K27M Specific Peptide Vaccine Combined with poly-ICLC with and without PD-1 inhibition using Nivolumab for the Treatment of newly diagnosed HLA-A2 (02:01)+ H3.3K27M Positive Diffuse Intrinsic Pontine Glioma (DIPG) and newly diagnosed HLAA2 (02:01)+ H3.3K27M Positive Gliomas
ClinicalTrials.gov Identifier: NCT02960230
PNOC019: A Randomized, Double-Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Combination Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma (HGG)
ClinicalTrials.gov Identifier: NCT04323046
Soon to open at the DIPG/DMG Center Zurich
Expected to open: Q3 2021
PNOC023: Open label Phase 1 and target validation study of ONC206 in children and young adults with newly diagnosed or recurrent diffuse midline glioma (DMG), and other recurrent malignant brain tumors
Expected to open: Q2/3 2021
PNOC026: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with BRAF-Altered, Recurrent or Progressive Low-Grade Glioma